1. Estimates of the health and economic burden of pneumococcal infections attributable to the 15-valent pneumococcal conjugate vaccine serotypes in the USA;Owusu-Edusei;Infect Dis Ther,2022
2. Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. adults: updated recommendations of the Advisory Committee on Immunization Practices—United States, 2022;Kobayashi;MMWR Morb Mortal Wkly Rep,2022
3. Burden of acute-care hospitalization for community-acquired pneumonia in Canadian adults aged 50 years or older: focusing on most responsible diagnosis tells only part of the story;Grajales Beltrán;Vaccines (Basel),2023
4. Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) report, Emerging Infections Program Network, Streptococcus pneumoniae, 2019. https://www.cdc.gov/abcs/downloads/SPN_Surveillance_Report_2019.pdf, [accessed 7 September 2023].
5. Impact of 13-valent pneumococcal conjugate vaccine (PCV13) on non-bacteremic pneumococcal pneumonia (NBPP) among adults in the United States, 2013-2017;Gierke;Open Forum Infect Dis,2020